GLUCAGON-like peptide-1 agonistsTYPE 2 diabetesBLOOD sugarHYPOGLYCEMIC agentsGlucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
BPG致力于知识的发现和传播 Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease Maurizio Soresi, Lydia Giannitrapani Maurizio Soresi, Lydia Giannitrapani,Department of Health Promotion Sciences, Maternal and Infant Care, Internal...
近年来,GLP-1 受体激动剂(Glucagon-like peptide-1 receptor agonists, GLP-1RA)因在控制血糖和减重方面的良好疗效受到广泛关注。 11月28日,在波士顿举行的肥胖症和NASH药物开发峰会上,Sagimet公司在报告中分享了一项关于NASH小鼠模型的研究结果。该结果表明,将一种与其药物denifanstat类似的新型脂肪酸合成酶(FASN)抑...
Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativaLinked Article: Jennings et al . Br J Dermatol 2017; 177 :858–859 .doi:10.1111/bjd.15742Emtestam, L.Sartorius, K.John Wiley & Sons, Ltd.British Journal of Dermatology...
Glucagon-like peptide 1 (GLP-1) is an intestine-derived insulinotropic hormone that stimulates glucose-dependent insulin production and secretion from pancreatic beta-cells. Other recognized actions of GLP-1 are to suppress glucagon secretion and hepatic glucose output, delay gastric emptying, reduce fo...
Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medi
In the past 2 decades, eight glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been approved for the management of type 2 diabetes, each with its peculiar molecular structure, pharmacokinetics, and metabolic effects. Along with their marked glucose-lowering actions, which occur both at ...
Thus, the exendin-4 backbone has been utilized in the creation of longer-acting synthetic GLP-1R agonists.Figure adapted from Glotfelty et al. [5]. 1.2. FDA approval of incretin-based therapies Various GLP-1 analogs have been developed to lengthen the half-life of the peptide and prolong ...
5.2Glucagon-like peptide analogs and agonists Glucagon-like peptide-1 (GLP-1), anincretin hormonesynthesized byLangerhans cellsin the intestinal tract in response to oral nutrient intake, has garnered significant attention as a potential therapeutic agent forT2DM. In particular, GLP...